Via data derived various primary secondary healthcare settings, able predict efficacy possible side effect medication. way PHARMO Institute want contribute health innovation health optimization. observational study disease-specific cohort created various databases. mission achieve greater insight real world healthcare, collection expert analysis patient-centric information. internal standardised procedure quality guideline accordance ENCePP Guide Methodological Standards Pharmacoepidemiology ENCePP Code Conduct (www.encepp.eu) guarantee high quality services. performing pharmacoepidemiological study including project management, methodology, data quality stakeholder communication European level. perform post-authorisation safety effectiveness study (PASS + PAES), drug utilisation study (DUR), study safety outcome many type study PHARMO Institute studying use, effectiveness side effect medicines, used daily practice many years. use large file data million patient investigate often medicine le effective even cause side effects. PHARMO Institute place turn need substantiated, authoritative evidence. Menu Dedicated research real-life healthcare PHARMO Institute PHARMO Institute dedicated study epidemiology, drug utilization, drug safety health outcomes. independent research organization, study effect drug treatment real life enhance health people using medication. way contribute drug safety able find unwanted side effect advance.We base study database derived general practitioners, hospitals, labs, different disease related database in- out-patient pharmacies, anonymized STIZON used follow disease course effect medication treatment. Via data derived various primary secondary healthcare settings, able predict efficacy possible side effect medication. way PHARMO Institute want contribute health innovation health optimization. observational study disease-specific cohort created various databases. use data 150 million person year 0 Patients 0 Practices primary secondary care 0 Founded 1999, PHARMO Institute independent research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. PHARMO Insitute developed maintains large high quality Database Network work closely (inter)national medical university European databases. study longitudinal real world patient data, PHARMO Institute contributes risk management outcome research provides solution decision-makers market access, health economics health outcome domains.Our mission achieve greater insight real world healthcare, collection expert analysis patient-centric information. News update Read latest update publication news section below. See Halifax ICPE 2023! proud Gold sponsor year look forward seeing PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce Myocarditis pericarditis associated SARS-CoV-2 vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARS-CoV-2 Members information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl Menu Dedicated research real-life healthcare PHARMO Institute PHARMO Institute dedicated study epidemiology, drug utilization, drug safety health outcomes. independent research organization, study effect drug treatment real life enhance health people using medication. way contribute drug safety able find unwanted side effect advance.We base study database derived general practitioners, hospitals, labs, different disease related database in- out-patient pharmacies, anonymized STIZON used follow disease course effect medication treatment. Via data derived various primary secondary healthcare settings, able predict efficacy possible side effect medication. way PHARMO Institute want contribute health innovation health optimization. observational study disease-specific cohort created various databases. use data 150 million person year 0 Patients 0 Practices primary secondary care 0 Founded 1999, PHARMO Institute independent research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. PHARMO Insitute developed maintains large high quality Database Network work closely (inter)national medical university European databases. study longitudinal real world patient data, PHARMO Institute contributes risk management outcome research provides solution decision-makers market access, health economics health outcome domains.Our mission achieve greater insight real world healthcare, collection expert analysis patient-centric information. News update Read latest update publication news section below. See Halifax ICPE 2023! proud Gold sponsor year look forward seeing PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce Myocarditis pericarditis associated SARS-CoV-2 vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARS-CoV-2 Members information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl Menu Dedicated research real-life healthcare PHARMO Institute PHARMO Institute dedicated study epidemiology, drug utilization, drug safety health outcomes. independent research organization, study effect drug treatment real life enhance health people using medication. way contribute drug safety able find unwanted side effect advance.We base study database derived general practitioners, hospitals, labs, different disease related database in- out-patient pharmacies, anonymized STIZON used follow disease course effect medication treatment. Via data derived various primary secondary healthcare settings, able predict efficacy possible side effect medication. way PHARMO Institute want contribute health innovation health optimization. observational study disease-specific cohort created various databases. use data 150 million person year 0 Patients 0 Practices primary secondary care 0 Founded 1999, PHARMO Institute independent research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. PHARMO Insitute developed maintains large high quality Database Network work closely (inter)national medical university European databases. study longitudinal real world patient data, PHARMO Institute contributes risk management outcome research provides solution decision-makers market access, health economics health outcome domains.Our mission achieve greater insight real world healthcare, collection expert analysis patient-centric information. News update Read latest update publication news section below. See Halifax ICPE 2023! proud Gold sponsor year look forward seeing PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce Myocarditis pericarditis associated SARS-CoV-2 vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARS-CoV-2 Members information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl Menu Expertise expertiseThe expert PHARMO Institute perform tailor-made observational research using real world data help client effectively bridge gap clinical trial data real world evidence. staff consists academically trained specialist epidemiology, pharmacotherapeutics, medicine informatics. PHARMO Institutes in-house expert performing pharmacoepidemiological study including project management, methodology, data quality stakeholder communication European level. perform , ,and many .PHARMO Institute us collection, management analysis in-house data source well data source partners. lead European study provide critical evidence context emerging standard study design, database analysis operations, quality assurance Europe.PHARMO Institute adheres high standard throughout research process based robust methodologies, transparency scientific independence. internal standardised procedure quality guideline accordance ENCePP Guide Methodological Standards Pharmacoepidemiology ENCePP Code Conduct () guarantee high quality services. use data 150 million person year 0 Patients 0 Practices primary secondary care 0 Data access time information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu PHARMO Data PHARMO DataThe longitudinal nature data PHARMO Institute ha access to, enables follow-up 10 million person well-defined population Netherlands average twelve years. Currently, 7 million active person 17 million inhabitant Netherlands captured. Data collection period, catchment area overlap data source differ. Therefore, final cohort size study depend data source included. data source linked annual basis, average lag time data one year. electronic patient record include information age, sex, socioeconomic status mortality. available information depends data source. use data 150 million person year 0 Patients 0 Practices primary secondary care 0 Data access Data source PHARMO Institute ha access study-specific datasets derived network electronic healthcare database encompassing anonymous data different primary secondary healthcare setting Netherlands. different data source linked patient level validated algorithms. ensure privacy data, collection, processing, linkage anonymisation data performed STIZON. STIZON independent, ISO/IEC 27001 certified foundation, act Trusted Third Party (TTP) data source PHARMO Institute. information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl Menu International collaboration International collaborationsWe collaborate database expert multi-country database study principle European Networkof Centres Pharmacoepidemiology & Pharmacovigilance (). dedicated excellence research adhering ENCePP Guide Methodological Standards promoting scientific independence transparency. registered study theEU PAS register, publicly accessible resource registration pharmacoepidemiological pharmacovigilance studies. SIGMA Consortium SIGMA Consortium contract-based alliance European Network Centres Pharmacoepidemiology Pharmacovigilance (ENCePP) research centre proven institutional pharmacoepidemiologic real-world evidence (PE/RWE) experience, providing one-stop shop research services. best go-to organisation comprehensive rigorous methodological research, launched enable multi-country study use common analysis study response treatment large populations.Specifically, SIGMA Consortium conduct following activities:Act trusted hub planning, design, contracting, analyses, delivery, interpretation dissemination European PE/RWE studies, providing one-stop shop entity request research services.Provide training education participation studies.Promote, conduct, facilitate innovative methodological researchThe SIGMA Consortium provide best evidence use, benefit harm medications, vaccine device improve public health patient care. mission provide trusted pharmacoepidemiologic real-world evidence (PE/RWE) European federated professional network excellence based ENCePP Code Conduct. information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Resource Library Recent study suggest woman susceptible diuretic-induced hyponatremia resulting hospital admission men. aim study wa confirm whether sex difference hyponatremia related hospital admission diuretic user remain adjusting several confounding variable age, dose, concurrent medication. 1 September 2023 high degree adherence direct oral anticoagulant essential reducing risk ischaemic stroke systemic embolism patient atrial fibrillation, owing rapid decline anticoagulation activity dos omitted (i.e. rebound effect). 1 September 2023 Due established teratogenicity valproates, EU risk minimisation measure (RMMs) pregnancy prevention programme (PPP) valproate updated March 2018. 9 June 2023 GPs shown important provider medical care pregnancy, however, little evidence exists awareness pregnancy prescribing medication women. AIM: ass GPs awareness pregnancy association prescribing medication potential safety risks. 9 June 2023 need updated incidence rate (IRs) Lyme borreliosis (LB) Europe, including Netherlands. estimated LB IRs stratified geographic area, year, age, sex, immunocompromised status, socioeconomic status (SES). 12 April 2023 COVID19 pandemic ha large impact worldwide known particularly affect older population. paper outline protocol external validation prognostic model predicting mortality risk presentation COVID19 older population. prognostic model originally developed adult population validated older population ( 70 year age) three healthcare settings: hospital setting, primary care setting, nursing home setting. 4 April 2023 large-scale COVID-19 vaccination campaign 2021 2022 led rapid increase number received adverse event report spontaneous reporting systems. background incidence naturally occurring medical event became increasingly relevant causality assessment potential association vaccines, novel approach signal detection wa warranted. O/E method useful approach signal detection potential adverse reaction handling large number ICSRs. research needed attest causality clinical basis. 15 March 2023 Low-dose rivaroxaban ha indicated management atherosclerotic cardiovascular disease (ASCVD) recent (2019-2020) update European guidelines. aimed describe prescription trend low-dose rivaroxaban ASCVD patient period 2015-2022 two European countries, compare trend guideline changes, determine characteristic user 8 March 2023 safety effectiveness rivaroxaban versus vitamin K antagonist (standard care [SOC]) stroke prevention patient nonvalvular atrial fibrillation (NVAF) wa evaluated Europe. Observational study conducted UK, Netherlands, Germany, Sweden. Primary safety outcome hospitalization intracranial hemorrhage, gastrointestinal bleeding, urogenital bleeding among new user rivaroxaban SOC NVAF; outcome analyzed using cohort (rivaroxaban SOC use) nested casecontrol design (current v nonuse). Statistical analysis comparing rivaroxaban SOC cohort performed. 16 February 2023 Patient characteristic new rivaroxaban user non-valvular atrial fibrillation changed 2011 2016/17, change differed countries. pattern methodological implications. considered interpretation observational study comparing effectiveness safety oral anticoagulants, especially regarding potential bias due unmeasured confounding. 1 February 2023 Page1 Filter Therapeutic area Type study information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Contact u Contact PHARMO InstituteIf question research services, please hesitate get touch us.The PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe NetherlandsT: E: (English version)(Dutch version) information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl Menu Resource Library Recent study suggest woman susceptible diuretic-induced hyponatremia resulting hospital admission men. aim study wa confirm whether sex difference hyponatremia related hospital admission diuretic user remain adjusting several confounding variable age, dose, concurrent medication. 1 September 2023 high degree adherence direct oral anticoagulant essential reducing risk ischaemic stroke systemic embolism patient atrial fibrillation, owing rapid decline anticoagulation activity dos omitted (i.e. rebound effect). 1 September 2023 Due established teratogenicity valproates, EU risk minimisation measure (RMMs) pregnancy prevention programme (PPP) valproate updated March 2018. 9 June 2023 GPs shown important provider medical care pregnancy, however, little evidence exists awareness pregnancy prescribing medication women. AIM: ass GPs awareness pregnancy association prescribing medication potential safety risks. 9 June 2023 need updated incidence rate (IRs) Lyme borreliosis (LB) Europe, including Netherlands. estimated LB IRs stratified geographic area, year, age, sex, immunocompromised status, socioeconomic status (SES). 12 April 2023 COVID19 pandemic ha large impact worldwide known particularly affect older population. paper outline protocol external validation prognostic model predicting mortality risk presentation COVID19 older population. prognostic model originally developed adult population validated older population ( 70 year age) three healthcare settings: hospital setting, primary care setting, nursing home setting. 4 April 2023 large-scale COVID-19 vaccination campaign 2021 2022 led rapid increase number received adverse event report spontaneous reporting systems. background incidence naturally occurring medical event became increasingly relevant causality assessment potential association vaccines, novel approach signal detection wa warranted. O/E method useful approach signal detection potential adverse reaction handling large number ICSRs. research needed attest causality clinical basis. 15 March 2023 Low-dose rivaroxaban ha indicated management atherosclerotic cardiovascular disease (ASCVD) recent (2019-2020) update European guidelines. aimed describe prescription trend low-dose rivaroxaban ASCVD patient period 2015-2022 two European countries, compare trend guideline changes, determine characteristic user 8 March 2023 safety effectiveness rivaroxaban versus vitamin K antagonist (standard care [SOC]) stroke prevention patient nonvalvular atrial fibrillation (NVAF) wa evaluated Europe. Observational study conducted UK, Netherlands, Germany, Sweden. Primary safety outcome hospitalization intracranial hemorrhage, gastrointestinal bleeding, urogenital bleeding among new user rivaroxaban SOC NVAF; outcome analyzed using cohort (rivaroxaban SOC use) nested casecontrol design (current v nonuse). Statistical analysis comparing rivaroxaban SOC cohort performed. 16 February 2023 Patient characteristic new rivaroxaban user non-valvular atrial fibrillation changed 2011 2016/17, change differed countries. pattern methodological implications. considered interpretation observational study comparing effectiveness safety oral anticoagulants, especially regarding potential bias due unmeasured confounding. 1 February 2023 Page1 Filter Therapeutic area Type study information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Expertise expertiseThe expert PHARMO Institute perform tailor-made observational research using real world data help client effectively bridge gap clinical trial data real world evidence. staff consists academically trained specialist epidemiology, pharmacotherapeutics, medicine informatics. PHARMO Institutes in-house expert performing pharmacoepidemiological study including project management, methodology, data quality stakeholder communication European level. perform , ,and many .PHARMO Institute us collection, management analysis in-house data source well data source partners. lead European study provide critical evidence context emerging standard study design, database analysis operations, quality assurance Europe.PHARMO Institute adheres high standard throughout research process based robust methodologies, transparency scientific independence. internal standardised procedure quality guideline accordance ENCePP Guide Methodological Standards Pharmacoepidemiology ENCePP Code Conduct () guarantee high quality services. use data 150 million person year 0 Patients 0 Practices primary secondary care 0 Data access time information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu News See Halifax ICPE 2023! proud Gold sponsor year look forward seeing ICPE 2023 annual meeting weeks!We would love speak conference area expertise, including Oncology, Hematology, Diabetes, Cardiovascular, Central Nervous System, Respiratory, Nephrology, Maternal Care.Be sure catch three oral presentation eight poster conference!Oral PresentationsImpact COVID-19 Pandemic Netherlands Primary Healthcare Use Clinical Outcomes People Type 2 DiabetesRisk cardiovascular event exacerbation chronic obstructive pulmonary disease: cohort study using PHARMO Data NetworkImpact 2018 EU risk minimization measure revised pregnancy prevention program utilization prescribing trend valproates (Utrecht University)PostersExploring heterogeneity result multi-database studies: example using EXACOS-CV programUsing real-world general practitioner data study diagnosis management dementia: rationale designSurvival drug treatment pattern patient multiple myeloma triple exposure daratumumab, proteasome inhibitor immunomodulatory drugsPrevalence Risk Categories Chronic Kidney Disease without Type 2 DiabetesReal-World Data Lung Cancer: Safety?Type 2 Diabetes, Epidemic: Trends Incidence Prevalence, 2004-2020Vaccination utilisation pattern VAC4EU active safety surveillance study COVID-19 mRNA vaccine (Comirnaty) five European countriesSafety JCOVDEN vaccine (Ad26.COV2. S) using VAC4EU European Healthcare Data: Methods result first feasibility assessmentContact u schedule time meet u conference, connect attending staff, including:Ron Herings, DirectorJetty Overbeek PhD, Head PHARMO ResearchJosine Kuiper PhD, Senior Business Development ManagerEline Houben PhD, Senior Research ManagerKarin Swart PhD, Senior Research ManagerJesse van den Berg, PhD Candidate ResearcherNaomi Boxall PhD, Chief Operating OfficerBe sure stop exhibit booth #506 speak u get information new partnership Lumanity See soon! Share article information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu News PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce partnership Lumanity, organization dedicated accelerating optimizing access medical advances.Lumanity applies incisive thinking decisive action cut complex situation deliver transformative outcome accelerate optimize access medical advances. transforming data information real world insight evidence, Lumanity power successful commercialization empowers patients, providers, payers, regulator take timely decisive action.The PHARMO Institutes service highly synergistic Lumanitys, company share mission optimize patient access therapy focus demonstrating real world safety effectiveness. working together, PHARMO Institute Lumanity able offer global RWE capability expert based US EU.Dutch healthcare data one detailed RWE source world, representative Western Europe, rich abundant primary care data, say Prof. Dr. Ron Herings, founder director PHARMO Institute. Im happy found deeply science-oriented mission aligned international partner enable us, extension Netherlands, play much greater role addressing global research question facing researchers.This partnership signifies enthusiasm dedication expanding RWE space providing client deeper capability direct access patient level data, add Gema Parlange, Global Practice Lead RWE Lumanity. great team expert across Lumanity, ask right questions, know partner, consider whole product lifecycle, understand embrace regulatory requirements. look forward expanding amplifying expertise working knowledgeable RWE expert PHARMO.Moving forward, PHARMO Institute Lumanity continue generate evidence safety, effectiveness, value medicine betterment patient care EU, around world. plan continue collaborate expand RWE space, addressing global use case pharmacoepidemiology, health economics, outcome research. learn RWE capability collaborating Lumanity. Share article information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu News Myocarditis pericarditis associated SARS-CoV-2 vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARS-CoV-2 vaccines: population-based descriptive cohort nested self-controlled risk interval study using electronic health care data four European country Frontiers Pharmacology. multi-country study used data four countries, researcher studied first myo-/pericarditis diagnosis exposure first second dose Pfizer, AstraZeneca, Moderna, Janssen COVID-19 vaccines. study followed design population-based cohort study nested self-controlled risk interval (SCRI). Individuals followed 01/01/2020 end data availability (31/12/2021 latest). 35 million individual (492% women, median age 3949years) included, 574% received least one COVID-19 vaccine dose. Baseline incidence myocarditis wa low. Myocarditis IRRs elevated vaccination aged < 30years, Pfizer vaccine dos (IRR = 33, 95%CI 12-9.4; 78, 95%CI 26-235, respectively) Moderna vaccine dose 2 (IRR = 61, 95%CI 11-335). effect AstraZeneca vaccine dose 2 could excluded (IRR = 242, 95%CI 096-607). Pericarditis wa associated vaccination. Important note absolute incidence myocarditis remains low. Please read check detailed methodology results. Share article information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Contact u Contact PHARMO InstituteIf question research services, please hesitate get touch us.The PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe NetherlandsT: E: (English version)(Dutch version) information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl Menu Subscribe newsletter Subscribe newsletter Subscribe newsletter First name * Last name * Company City Email * Telephone Captcha Past Newsletters Q4 2022: Q4 2022: Q3 2022: Q2 2022: Q1 2022: information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Downloads DownloadsAnnual reportsEach year develop ourto inform healthcare provider contribute PHARMO Data Network work previous year. report describes highlight previous year like recently initiated collaboration external partners, Profiling Parkinsons disease ProPark Consortium Personalized Medicine Approach Alzheimers Disease ABOARD project, Vaccine monitoring Collaboration Europe VAC4EU.View annual report (in Dutch): information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu STIZON Stichting Informatievoorziening voor Zorg en Onderzoek (STIZON) PHARMO Database Network created , STIZON act Trusted Third Party (TTP) data source PHARMO Institute. STIZON authorised data provider manage process identifiable patient data. STIZON collect maintains identifiable patient data retrieved various healthcare provider (e.g. general practitioner pharmacists) link data patient level. PHARMO Database Network used research PHARMO Institute data depleted personal information may traced back person (such date birth). information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu us? us? point lives, use form medication. aspirine headach, vaccination resist virus, antibiotic eliminate bacterial infection perhaps longer trial te fight cancer. chronical disease patient bound medicine rest lives. Medicines always promise do. Due physical difference difference daily use medicine, effect medicine vary strongly.At PHARMO Institute studying use, effectiveness side effect medicines, used daily practice many years. use large file data million patient investigate often medicine le effective even cause side effects.PHARMO Institute place turn need substantiated, authoritative evidence. scientist firstacademically trained, credentialed researcher know apply appropriate research methodology realworld application situations. care whats right whats relevant, medical professional patient make good, safe, timely decision pharmaceutical products. information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Vacancies VacanciesTrue mission excel interest improving patient treatment care, operate entrepreneurial multidisciplinary environment. specialist recruit various backgrounds, including: epidemiologists, pharmacists, medical advisors, biostatisticians, programmer business marketing professionals. Together team brings scientific expertise healthcare market knowledge global clients.We always looking innovative, creative collaborative individual join team. sound like kind exciting, challenging environment seeking, please explore might become part team checking current opportunity sending letter outlining motivation curriculum vitae to:See vacancy below: (Vacancy Dutch) information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu News See Halifax ICPE 2023! proud Gold sponsor 3 August 2023 PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced 31 July 2023 Myocarditis pericarditis associated SARS-CoV-2 vaccine Together colleague across Europe recently 28 December 2022 DIAbetes MANagement Treatment (DIAMANT) Cohort DIAbetes MANagement Treatment (DIAMANT) Cohort 28 December 2022 Real-world data HER2-low metastatic breast cancer: population based cohort study study, 18 November 2022 Complex drug use number people using medicine combination medicine increasing, 3 November 2022 ISPOR Europe 2022 Vienna, INTREPID Trial study, PHARMO Institute 25 October 2022 study describes treatment patterns, low-density lipoprotein cholesterol (LDL-C) level healthcare resource utilization (HCRU) 24 October 2022 people living cancer. expected number 18 October 2022 PHARMO Institute ICPE Copenhagen PHARMO Institute team great time 30 August 2022 Page1 information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Terms & condition Terms & ConditionsOF:PHARMO Institute N.V.Van Deventerlaan 30-403528 AE UtrechtThe Netherlandshereinafter referred as: userArticle 1 Definitions1.In present general term conditions, following term used sense given below, unless explicitly indicated otherwise.PHARMO: user general term conditions.Client: user opposite party.Agreement: agreement concerning provision services.Article 2 General1.The present term condition shall apply every offer, tender agreement user client, user ha declared present term condition applicable, insofar party explicitly deviated present term condition writing.2.The present term condition shall also apply agreement user, execution call service third parties.3.Possible deviation present general term condition shall valid provided explicitly agreed upon writing.4.The applicability client possible purchase condition explicitly rejected.5.If one stipulation present general term condition null void declared null void, stipulation present general term condition shall remain fully applicable. case ensuing, user client shall enter negotiation agree upon new stipulation replacing null void conditions, or, case may be, condition declared null void, whereby purpose meaning original condition shall heeded far possible.Download complete. information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl use cooky ensure give best experience website. continue use site assume happy it. Menu Privacy policy Privacy policy Using PHARMO data use PHARMO data controlled independent Compliance Committee STIZON / PHARMO Institute. Compliance Committee STIZON / PHARMO Institute consists representative participating data supplier privacy expert (chairman committee). study requires permission Committee. Prior permission required dependent detail use data. study, research question, data used study, method used analyze data, people/organizations commissioned study described. decision Compliance Committee STIZON / PHARMO Institute based applicable legislation Netherlands, e.g. Personal Data Protection Act Medical Treatment Contract Act. Within legal framework, Code Conduct Use Data Health Research important document interpretation use kind data scientific research Netherlands, approved Dutch Data Protection Authority (). Informed Consent soon form intervention change routine care involved study, informed consent must obtained. addition, explicit ethical approval certified Ethical Committee must obtained. If, example, patient enrolled studies, additional test need performed context study, Dutch law mandate informed consent. is, clear distinction analysis routinely collected data, conducting study requires additional test procedures. study involves additional test procedure submitted certified Ethical Review Board Netherlands. information? question suggestion services? Please hesitate get touch u via button below. fill contact form contact page. look forward hearing you! Founded 1999, PHARMO Institute independent scientific research organisation dedicated study epidemiology, drug utilisation, drug safety, health outcomes, utilisation healthcare resources. Links Navigate Contact PHARMO InstituteVan Deventerlaan 30-403528 AE UtrechtThe Netherlands +31 30 7440 800 pharmo@pharmo.nl